Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Status:
Active, not recruiting
Trial end date:
2021-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Dasatinib when added to standard
chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome
positive acute lymphoblastic leukemia
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborators:
Children's Oncology Group EsPhALL EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib